It is well known that original solid Ritonavir capsules had to be withdrawn and replaced by solution-based refrigerated gel-capsules because of the appearance of more stable and less soluble polymorphic form. In recent years, solid heat-stable caps were launched, which should imply that the bioavailability problem was solved. However, I was not able to find any details as to how it was done. Can anyone suggest any publications on this development? Thank you
I'd start looking in the Drugs@FDA database. Look at all the label revisions and approval letters for ritonavir. There's probably one that describes their solution (unless redacted from the public domain). Hope this helps.
Thanks for the hint. Evidently AbbVie now uses 'amorphous dispersions' of Ritonavir in copovidone, prepared using the hot melt extrusion technology. Although some manufacturers from India also market (not in the US) classical-type hard gelatine capsules with supposedly equivalent PK.
solid dispersion may help to convert the ritonavir into amorphous so there are many methods for solid dispersion such as hot melt, kneading, solvent evaporation method etc so if you go through this it will help to solve the problem hope so
- Badges
- Science topic
- Similar topics
- Biological Science
- Bioecology
- Systems Ecology
- Landscape Ecology
- Connectivity